华东医药股份有限公司 关于全资子公司签署产品独家商业化合作协议的公告

Transaction Overview - On August 8, 2025, East China Pharmaceutical Co., Ltd. (the "Company") announced that its wholly-owned subsidiary, East China Pharmaceutical (Hangzhou) Co., Ltd., entered into an exclusive commercialization cooperation agreement with Jiangsu Weikail Pharmaceutical Technology Co., Ltd. for the product VC005 [2] - The agreement grants East China Pharmaceutical (Hangzhou) exclusive commercialization rights for VC005 in mainland China, with an upfront payment of 50 million RMB and potential milestone payments up to 180 million RMB [2][10] Parties Involved - East China Pharmaceutical (Hangzhou) Co., Ltd. is a wholly-owned subsidiary established in 2005, primarily engaged in the wholesale and retail of pharmaceutical products and medical devices [3] - Jiangsu Weikail Pharmaceutical Technology Co., Ltd., founded in 2010, focuses on innovative drug development and has a robust pipeline with multiple clinical projects targeting various diseases [4] Product Information - VC005 is a novel, potent, and highly selective second-generation oral JAK1 inhibitor, currently in clinical development for treating autoimmune diseases such as moderate to severe atopic dermatitis and ankylosing spondylitis [8] - The product has shown promising results in clinical trials, with efficacy comparable to existing treatments and a favorable safety profile [8][15] Financial Arrangements - The financial structure of the agreement includes a 50 million RMB upfront payment and milestone payments triggered by specific regulatory events, totaling up to 180 million RMB [10] Cooperation Significance - The partnership aims to address the urgent clinical needs in autoimmune diseases, particularly in the area of oral formulations, which are expected to enhance patient compliance and treatment accessibility [14][16] - The collaboration will enrich the Company's pipeline in dermatology and strengthen its competitive position in the autoimmune disease sector [17][18] Future Plans - The Company plans to utilize its existing commercial channels and expertise to promote VC005 effectively, aiming for a differentiated market position in the autoimmune treatment landscape [18][19]